CM
SIOX

Crestline Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Crestline Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,802
Closed -$334K – 183
2017
Q2 		$334K Buy
+1,802
New +$316K 0.04% 119

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Crestline Management's SIOX Position: Q3 2017 in Review

Crestline Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 1,802 shares — an estimated $334K sold.

Crestline Management first reported a position in SIOX in Q2 2017 and held it in 1 quarter. The position peaked at $334K in Q2 2017. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • Crestline Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 1,802 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $334K.
  • Crestline Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Crestline Management's Sio Gene Therapies Inc. Common Stock position peaked at $334K in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.